Caricamento...
Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
BACKGROUND: Lixisenatide is a once‐daily, prandial, short‐acting glucagon‐like peptide‐1 receptor agonist. Its main antidiabetic effect is to delay gastric emptying to control postprandial plasma glucose excursions. The dose–response relationship of the integrated insulinotropic and gastrostatic res...
Salvato in:
| Pubblicato in: | Diabetes Metab Res Rev |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4744661/ https://ncbi.nlm.nih.gov/pubmed/25773712 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/dmrr.2647 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|